WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

Download IconDownload Print IconPrint

WilmerHale Advises Alkermes in Acquisition of Rodin Therapeutics

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
On November 25, 2019, Alkermes plc announced the completion of its previously announced acquisition of Rodin Therapeutics, Inc., a privately held biopharmaceutical company focused on developing novel, small molecule therapeutics for synaptopathies. The WilmerHale team representing Alkermes was led by Stuart Falber, Joe Conahan and Mark Nylen and included Julie Hogan Rodgers, Scott Kilgore, Steve Barrett, Bruce Manheim, Barry Hurewitz, Hartmut Schneider, Paul Jakubowski, Ben Unger, Ben Kelsey, Lauren Ige, Meghan Fay and Meghan Muncey.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel